|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
5/18/2007 12:24:13 PM
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM) announced today the recent addition of Dr. Robert Swift as the new member of the Board of Directors of Xechem International, Inc. Dr. Swift received his Ph.D. in Biochemistry from Michigan State University and his M.B.A. in Finance from Indiana University. He has 15 years of experience in molecular biology, cancer research, biopharmaceuticals, and medical devices, and over ten years of experience in drug research and pre-clinical development with Eli Lilly and Company. He worked as a biotechnology analyst and an investment banker for five years, and was the Director of Research in Life Sciences at C.E. Unterberg, Towbin. In 2001, he joined Origin Capital Management and was co-portfolio manager until 2004. Presently he serves as a healthcare consultant.
|
|
|
|
|
|
|
|
|
|
|